title: Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit.
abstract: OBJECTIVE
  Increasing attention to quality of life and to health care costs has recently induced several cancer centers to change in-patient management into an out-patient setting even during high risk phases of disease. The aim of this prospective study was to evaluate feasibility and safety, as well as clinical characteristics, of out-hospital management of AML patients during their post-consolidation phase.
  
  
  METHODS
  All patients who were treated over a three year period by the three following protocols were included in the study: AML10 EORTC/GIMEMA for patients with AML, except for APL, aged </= 60 years; AML 13 EORTC/GIMEMA, for patients with AML, except for APL, aged >60 years; AIDA GIMEMA for APL patients. All patients submitted to the AML10 and AML13 protocols and those patients submitted to the AIDA protocol with difficult peripheral vein access had a central venous catheter (CVC) sited. Patients treated as in-patients were discharged at the end of consolidation chemotherapy provided they were in a good clinical condition. They were routinely evaluated on an out-patient basis twice weekly. In the event of any complication they were referred to the Emergency Unit of our Department dedicated to out-patients with hematologic diseases.
  
  
  RESULTS
  One hundred and eleven patients with AML were eligible for intensive chemotherapy. After achievement of complete remission they received a total of 133 consolidation courses and in 127 instances they were followed on an out-patient basis during the aplastic phase. There were 69 cases (54%) of rehospitalization, 68 because of fever and only one because of severe anemia. Rehospitalization occurred in 90%,70% and 38% of courses in AML10, AML13 and AIDA protocols, respectively. Only one patient died: the cause of death was a brain hemorrhage. Coagulase negative staphylococci and viridans streptococci were the organisms most frequently isolated from blood. Most coagulase negative staphylococci were isolated in patients submitted to AML10 and AML13 protocols, who had an indwelling CVC. Empiric once-a-day antibacterial therapy with ceftriaxone and amikacin was effective in 75% of the cases and made early discharge possible in 28% of the cases with antibiotic therapy continued in an out-patient setting. Overall, patients were managed out of the hospital for 66% of the period of post-consolidation neutropenia (77%, 48% and 50% of the post-consolidation neutropenia period in patients treated with AIDA, AML10 and AML13 protocols, respectively).
  
  
  CONCLUSIONS
  Thanks to the availability of an emergency unit specifically dedicated to out-patients with hematologic diseases, selected out-hospital management of AML patients during post-consolidation cytopenia is a feasible, well accepted and cost-saving option, and can contribute to lower the risk of developing severe nosocomial infections. The empiric therapy with once-a-day ceftriaxone plus amikacin was effective, with the exception of staphylococcal infections, and made it possible to discharge patients early to continue treatment in an out-patient setting.
authors.affiliation: Dipartimento di Biotecnologie Cellulari ed Ematologia, University "La Sapienza", Via Benevento 6, 00161, Rome, Italy. girmenia@bce.med.uniroma1.it
authors.forename: C
authors.initials: C
authors.lastname: Girmenia
authors.forename: G
authors.initials: G
authors.lastname: Alimena
authors.forename: R
authors.initials: R
authors.lastname: Latagliata
authors.forename: S G
authors.initials: SG
authors.lastname: Morano
authors.forename: F
authors.initials: F
authors.lastname: Celesti
authors.forename: L
authors.initials: L
authors.lastname: Coppola
authors.forename: A
authors.initials: A
authors.lastname: Spadea
authors.forename: S
authors.initials: S
authors.lastname: Tosti
authors.forename: S
authors.initials: S
authors.lastname: Mecarocci
authors.forename: G M
authors.initials: GM
authors.lastname: D'Elia
authors.forename: A
authors.initials: A
authors.lastname: Tafuri
authors.forename: G
authors.initials: G
authors.lastname: Cimino
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
mesh_terms: D000328:Adult; D000553:Ambulatory Care / Q000458:organization & administration*; D000583:Amikacin / Q000627:therapeutic use; D000740:Anemia / Q000209:etiology / Q000628:therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D002443:Ceftriaxone / Q000627:therapeutic use; D002543:Cerebral Hemorrhage / Q000209:etiology; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004636:Emergency Service, Hospital; D005334:Fever / Q000209:etiology / Q000628:therapy; D006760:Hospitalization; D006801:Humans; D016867:Immunocompromised Host; D007558:Italy / Q000453:epidemiology; D007951:Leukemia, Myeloid / Q000150:complications* / Q000188:drug therapy; D007958:Leukocyte Count; D008875:Middle Aged; D009181:Mycoses / Q000209:etiology / Q000628:therapy; D009503:Neutropenia / Q000209:etiology; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology
chemical_list: D002443:Ceftriaxone; D000583:Amikacin